Skip to content


As a privately held company, Servier has the ability to think and invest for the long-term. During our initial five years in the oncology space, Servier in the U.S. has more than doubled its portfolio and launched several new indications for IDH1-mutant cancers, including frontline AML, myelodysplastic syndromes (MDS) and previously treated cholangiocarcinoma (CCA) – many of these indications serving as a best-in-class treatment option.  

Oncology Pipeline

These programs are investigating treatments or outcomes that have not received approval from a health authority. The information presented is not intended to convey conclusions of safety or efficacy. There is no guarantee that the outcome of these studies will result in approval by a health authority.